ONIVYDE®
is a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. By blocking the enzyme, cancer cells are prevented from multiplying and eventually die.
PharmaEngine, Inc.
We Race With You
Virtual Pharmaceutical Company Business Model
Latest News
-
2025-02-05
PharmaEngine to receive US$50 million in milestone payment as ONIVYDE's 2024 sales in Europe and Asia had reached second milestone
-
2024-11-04
PharmaEngine and Haihe Biopharma enter into exclusive distribution agreement for LIPORAXEL®
-
2024-04-24
PharmaEngine announces first patient dosed in Phase I trial of PEP07 for solid tumor cancers